Roche’s cobas HPV Test Receives the US FDA’s Approval for cobas 6800/8800 System to Identify Women at Risk for Cervical Cancer

 Roche’s cobas HPV Test Receives the US FDA’s Approval for cobas 6800/8800 System to Identify Women at Risk for Cervical Cancer

Roche’s cobas HPV Test Receives the US FDA’s Approval for cobas 6800/8800 System to Identify Women at Risk for Cervical Cancer

Shots:

  • The US FDA approved Roche’s cobas HPV test for use on cobas 6800/8800 systems that enable molecular laboratories to achieve the efficiency and scale needed for meeting the demands of high-volume cervical screening programs
  • The approval is based on IMPACT study assessing cobas HPV test in ~ 35,000 women to clinically validate the test for use on the cobas 6800/8800 systems. The goal of cervical cancer screening is to find precancer early to stop the progression of disease
  • The cobas HPV test is indicated for routine cervical cancer screening including triage of ASC-US cytology, co-testing (or adjunctive screen) with cytology, and HPV primary screening of women to assess the risk for cervical pre/ cancer. Earlier, the test was approved for the cobas 4800 System to screen primary cervical cancer without accompanying Pap cytology in 2014

Click here to­ read full press release/ article | Ref: Roche  | Image: Life Science IP Review

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post